Despite widespread belief among cancer patients and health care professionals that acupuncture helps relieve nausea caused by cancer treatment, new research in radiotherapy has found it does not.
New research has yielded a clearer picture of which biomarkers could help doctors more precisely target the treatment of colon cancer, bringing closer the day when patients who will not benefit from chemotherapy are spared it, while those that will, get the more aggressive treatment they need.
A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.
Paying close attention to how a canary learns a new song has helped scientists open a new avenue of research against Huntington’s disease – a fatal disorder for which there is currently no cure or even a treatment to slow the disease.
Because racial or ethnic differences in response to antihypertensive drug therapies may contribute to disparities in cardiovascular disease, this systematic review of 28 studies attempts to (1) identify racial differences in the efficacy of antihypertensive drug therapies and (2) quantify the number and proportion of racial and ethnic minorities participating in these clinical trials.
An alternative design for phase II cancer clinical trials may improve success rates for new cancer drugs in phase III trials.
The difficulty in penetrating tumors and reaching all of the cancer cells is an important but under-appreciated cause of drug resistance in solid tumors, according to a review article.
The European Commission has approved Exelon® patch (rivastigmine transdermal patch), an innovative way to deliver this effective medicine to patients suffering from mild to moderately severe Alzheimer’s disease.
Childhood brainstem gliomas (BSGs) are rare but can be very difficult to treat successfully and they tend to have poor survival rates. However, a team of Spanish researchers have found that a chemotherapy regimen of irinotecan and cisplatin (I/C) produced rapid clinical responses and shrank the tumours by more than 20 percent in all six children enrolled in a clinical trial.
A report from the American Cancer Society finds the breast cancer death rate in the United States continues to drop more than two percent per year, a trend that began in 1990 and is credited to progress in early detection and treatment.